Original articles

Methyl-CpG binding protein 2 is associated with the prognosis and mortality of elderly patients with hip fractures

Xuejian Gao, Shan Xue, Fuqiang Yang, Baoling Wu, Xiaojing Yu, Baoquan An*

Department of Orthopedics, The 80th Army Hospital of Chinese People’s Liberation Army, Weifang, Shandong, China

HIGHLIGHTS

- MECP2 was downregulated in elderly patients with hip fracture.
- MECP2 was correlated with inflammatory factors in hip fractures.
- Lower MECP2 predicted poor clinical outcomes of hip fractures.
- Lower MECP2 predicted higher mortality and postoperative complications.

ARTICLE INFO

Keywords: MECP2; Prognosis; Hip fracture

ABSTRACT

Objectives: To investigate the expression level and clinical significance of Methyl-CpG binding Protein 2 (MECP2) in elderly patients with hip fractures.

Methods: This prospective observational study included 367 elderly patients with hip fractures between April 2016 and December 2018. All the patients were treated with internal fixation or joint replacement. In addition, 50 healthy elderly individuals were enrolled as healthy controls. The serum levels of MECP2 and inflammatory factors Interleukin (IL)-1β, IL-6, IL-8, and Tumor Necrosis Factor (TNF)-α was determined by enzyme-linked immunosorbent assay. Data on patients' basic characteristics and postoperative complications were collected. The Harris score was used to assess hip function at 1-month, 3-months, and 6-months after surgery. Patient quality of life was measured using the Barthel Index (BI) score 3-months after surgery. The 1-year mortality was analyzed using the Kaplan-Meier curve, and logical regression was used to analyze the risk factors for mortality.

Results: No significant differences were observed in the basic clinical characteristics of all patients. The serum MECP2 levels were remarkably high in patients with hip fractures and negatively correlated with serum IL-1β, IL-6, and TNF-α levels. Patients with higher MECP2 predicted higher dynamic Harris scores, lower postoperative complications, lower 1-year mortality, and higher BI scores. Logical regression showed that age was the only independent risk factor for postoperative 1-year mortality in elderly patients with hip fractures.

Conclusion: Lower MECP2 predicted poor prognosis and higher 1-year mortality in elderly patients with hip fractures.

Introduction

With the trend of population aging, related diseases, including fractures, are increasingly common, with an increasing incidence in many regions. Hip fractures account for the majority of osteoporotic fragility fractures, and more than 40% of the burden of osteoporosis worldwide is caused by hip fractures. For elderly patients, a hip fracture may lead to morbidity, mortality, and high costs of health and social care, and a deeper understanding of the risk factors for the prognosis of hip fracture is still needed.

Methyl-CpG binding Protein 2 (MECP2) is a protein that can bind methylated deoxyribonucleic acid and is involved in many diseases such as seizures, Rett's syndrome, and chronic pain. It has been observed that MECP2 can suppress inflammation, which is considered a risk factor for hip fractures. In recent decades, MECP2 was also found to be associated with bone formation. However, few
studies have focused on the clinical significance of MECP2 in hip fractures.

In the present study, the authors demonstrated that lower expression of MECP2 was correlated with a poor prognosis in patients with hip fractures, which might provide evidence for the role of MECP2 in the process of hip fractures.

Materials and methods

Patients

The present prospective observational study included 367 elderly patients with hip fractures who were admitted to the authors' hospital between April 2016 and December 2018. All patients were consecutively enrolled in this study. The inclusion criteria were as follows: 1) Patients ≥ 65 years of age; 2) Patients were radiographically diagnosed with femoral neck or intertrochanteric fractures; 3) Patients were American Society of Anesthesiologists (ASA) stage I–II; 4) Patients were hospitalized within 48h after the fracture. The exclusion criteria were as follows: 1) Patients with other fractures; 2) Pathological hip fractures caused by a tumor; 3) Patients with mental diseases such as schizophrenia; 4) Patients with severe renal, liver, or cardiovascular diseases, such as severe diabetic nephropathy, heart failure, hepatitis, and other surgical contraindications. Additionally, 50 healthy elderly individuals who underwent routine physical examinations were enrolled as healthy controls. All healthy individuals underwent routine physical examination and were confirmed as not having any diseases that might have influenced the study. This study was approved by the ethics committee of the 89th Army Hospital of the Chinese People’s Liberation Army.

For surgical methods, non-displaced femoral neck fractures and simple intertrochanteric fractures were mainly treated by internal fixation, including hollow screw fixation and dynamic hip screw fixation. For displaced femoral neck fractures and severely displaced and comminuted intertrochanteric fractures, total hip replacement or artificial femoral head replacement was selected according to the patient's condition. All implants were cemented. All surgical procedures were routine and were conducted by the same surgical team according to the same protocol.

Serum levels of MECP2 and inflammatory factors

Blood samples from all patients were collected within 24h after admission before undergoing surgery. Serum levels of MECP2 and inflammatory factors Interleukin (IL)-1β, IL-6, IL-8, and Tumor Necrosis Factor (TNF)-α were determined by Enzyme-Linked Immunosorbent Assay (ELISA) using commercially available ELISA kits according to the manufacturer's instructions.

Data collection and measurement

Demographic data, including age, sex, Body Mass Index (BMI), and clinical data, including the surgical type, ASA stage, fracture type, preoperative complications, and postoperative complications, were collected. For hip function, the Harris score was used before surgery and at 1-month, 3-months, and 6-months after surgery. The Barthel Index (BI) score was used to measure patient quality of life 3-months after surgery. For survival analysis, the survival duration was defined as the time from hospital admission to death or the last follow-up. All patients were followed up for 1-year. Patients who were lost to follow-up were excluded.

Statistical analysis

The measurement data are expressed as the mean ± standard deviation. The Chi-Square analysis was used to compare rates. Comparisons between two groups were conducted using Student’s t-test. The Kaplan-Meier (K-M) curve was used for 1-year survival analysis. Pearson's correlation assay was used for the correlation analysis. Binary regression analysis was used to analyze 1-year mortality risk factors using a back step. Differences were considered statistically significant when the p-value was < 0.05. All calculations were performed using SPSS version 20.0.

Results

Basic characteristics of all patients

Among all patients, the mean age was 79.64±9.34 years, with 163 males and 204 females. In terms of fracture type, 231 (62.94%) patients had femoral neck fractures, and 136 (37.06%) had intertrochanteric fractures. The surgical strategies were simple fractures with fixation for 80 (21.80%) patients, complex fractures with fixation for 76 (20.71%) patients, simple fractures with arthroplasty for 112 (30.52%) patients, and complex fractures with arthroplasty for 99 (26.98%) patients. No significant difference was observed in the basic characteristics of age, sex, and BMI between the patients and healthy controls (Table 1).

MECP2 was decreased in patients with hip fractures and was correlated with IL-1β, IL-6, and TNF-α

Serum MECP2 levels and inflammatory factors IL-1β, IL-6, IL-8, and TNF-α were measured. The MECP2 levels were markedly lower in patients with hip fractures than in healthy controls (p < 0.05), while the levels of IL-1β, IL-6, IL-8, and TNF-α were significantly higher in patients with hip fractures (p < 0.05) (Fig. 1). Pearson's analysis showed that MECP2 was negatively correlated with IL-1β, IL-6, and TNF-α (p < 0.05) (Table 2). However, the authors did not observe significant differences in MECP2 and inflammatory factors among patients who underwent different surgical methods (Fig. 2).

Lower MECP2 predicted a lower Harris score, poor quality of life, and more complications

To further investigate the relationship between MECP2 and the prognosis of patients with hip fractures, the patients were divided into two groups (MECP2 high/low groups) based on the mean MECP2 value (3.26 ng/mL). The dynamic Harris score was evaluated. The hip function improved after surgery in all patients. However, patients with higher MECP2 levels showed higher mean Harris scores than those with lower MECP2 levels (p < 0.05) (Fig. 3). The BI index also showed that patients with higher MECP2 levels had higher BI

Table 1: Basic characteristics of all patients and participants.

| Variables                  | Hip fracture, (n = 367) | Healthy controls, (n = 50) | p     |
|----------------------------|-------------------------|----------------------------|-------|
| Age, year                  | 79.64±9.34              | 78.90±9.71                 | 0.601 |
| Sex, female (%)            | 204 (55.59)             | 27 (54.00)                 | 0.821 |
| BMI, kg/m²                 | 21.57±1.99              | 21.39±1.90                 | 0.544 |
| Fracture type, n (%)       | 231 (62.94)             |                           |       |
| Femoral neck fracture      | 136 (37.06)             |                           |       |
| Intertrochanteric fracture | 213 (62.94)             | 136 (37.06)                |       |
| Fixation                   |                         |                           |       |
| Simple fractures            | 80 (21.80)              |                           |       |
| Complex fractures           | 76 (20.71)              |                           |       |
| Arthroplasty                |                         |                           |       |
| Simple fractures            | 112 (30.52)             |                           |       |
| Complex fractures           | 99 (26.98)              |                           |       |

BMI, Body Mass Index.
values (p < 0.05) (Table 3). The total complication rate was also higher in patients with lower MECP2 levels (p < 0.05). These results indicate that MECP2 is correlated with the postoperative prognosis of patients with hip fractures.

Finally, the authors analyzed the 1-year mortality and survival conditions of the patients. Patients with higher MECP2 had a lower mortality rate and longer survival compared to those with lower MECP2 levels. This finding suggests a positive correlation between MECP2 levels and patient survival after hip fracture surgery.

**Fig. 1.** Serum MECP2 and inflammatory factor levels in patients with hip fractures and healthy controls. ***p < 0.001 vs. control. MECP2, Methyl-CpG binding Protein 2; IL, Interleukin; TNF, Tumor Necrosis Factor
Discussion

Hip fracture is one of the most common causes of fractures in elderly people. Despite surgical development, the mortality rate for elderly patients with hip fractures is still high; thus, new diagnosis and prognosis biomarkers may benefit patient treatment. In the present study, the authors demonstrated that MECP2 was downregulated in patients with hip fractures and correlated with the postoperative prognosis of elderly patients with hip fractures.

MECP2 has been shown to be associated with bone formation and related processes. It was found that a decrease in MECP2 might cause dysfunction in bone formation and reduce the bone volume in Rett’s syndrome. Another study showed that MECP2 promoted fibrosis and myofibroblast trans-differentiation through an epigenetic pathway. In addition, inhibition of MECP2 might lead to suppression of osteogenic differentiation and cell apoptosis of human periodontal ligament fibroblasts. In bone recovery and wound healing, osteogenic differentiation and myofibroblast trans-differentiation are both important and may facilitate recovery duration, as well as fracture healing. Thus, the authors can speculate that MECP2 may also be associated with fracture healing through the regulation of osteogenic differentiation and myofibroblast trans-differentiation. In this study, the authors observed that MECP2 was downregulated in patients with hip fractures and was correlated with patient prognosis, which supports the above speculation.

Table 2
Correlation among MECP2 and IL-1β, IL-6, IL-8, and TNF-α.

|          | MECP2  | IL-1β | IL-6 | IL-8 | TNF-α |
|----------|--------|-------|------|------|-------|
| Pearson’s correlation | MECP2 | 1     | -0.654 | -0.676 | -0.666 | -0.714 |
| p        | -      | 0.000 | 0.000 | 0.000 | 0.000 |
| Pearson’s correlation | IL-1β | 0.654 | 1     | 0.599 | 0.598 | 0.662 |
| p        | -      | 0.000 | 0.000 | 0.000 | 0.000 |
| Pearson’s correlation | IL-6  | -0.676 | 0.599 | 1     | 0.610 | 0.672 |
| p        | -      | 0.000 | 0.000 | 0.000 | 0.000 |
| Pearson’s correlation | IL-8  | -0.666 | 0.598 | 0.610 | 1     | 0.661 |
| p        | -      | 0.000 | 0.000 | 0.000 | 0.000 |
| Pearson’s correlation | TNF-α | -0.714 | 0.662 | 0.672 | 0.661 | 1     |
| p        | -      | 0.000 | 0.000 | 0.000 | 0.000 |

MECP2, Methyl-CpG binding Protein 2; IL, Interleukin; TNF, Tumor Necrosis Factor.

Fig. 2. MECP2 and inflammatory factors among patients with different surgical methods. MECP2, Methyl-CpG binding Protein 2; IL, Interleukin; TNF, Tumor Necrosis Factor.

Fig. 3. The dynamic change in the Harris score. MECP2, Methyl-CpG binding Protein 2; mon, month.
in lung injury. On the contrary, the inflammatory response could also induce MECP2 to regulate microglial and macrophage gene expression.\textsuperscript{20} Li et al. demonstrated that MECP2 promotes the expression of forkhead box P3 and protects against inflammation by promoting regulatory T-cells.\textsuperscript{21} In addition, the lack of MECP2 also induced inflammatory factors such as IL-6 and TNF-$\alpha$ by activating nuclear factor-kappa B signaling.\textsuperscript{22} All these studies indicated that MECP2 acts as an inflammation suppressor. In the present research, the authors also found that MECP2 was negatively correlated with the inflammatory factors IL-1, IL-6, and TNF-$\alpha$, which was consistent with the above studies. The stimulation of inflammatory factors is usually seen in patients with hip fractures, and higher inflammatory factors are correlated with poor prognosis.\textsuperscript{23-25} The authors’ results implied that MECP2 might also be involved in hip fracture promotion through regulation of inflammation, which needs to be confirmed with further studies.

### Conclusion

In conclusion, through this observational study, the authors observed that MECP2 was downregulated in patients with hip fractures, and lower MECP2 levels predicted poor prognosis in elderly patients with hip fractures. This study might provide novel insights into the role of MECP2 in hip fractures. More research is needed to further demonstrate the molecular mechanisms of MECP2 in fracture recovery and related processes.

### Authors’ contributions

Gao X conducted the experiments and wrote the original manuscript draft. Xue S collected and analyzed the data. Yang F, Wu B and Yu X collected the data. An B analyzed the data and reviewed the manuscript.

### Declaration of Competing Interest

The authors declare no conflicts of interest.

### References

1. Schaap LA, Van Schoor NM, Lijm P, Visser M. Associations of sarcopenia definitions, and their components, with the incidence of recurrent falling and fractures: the longitudinal aging study Amsterdam. J Gerontol A Biol Sci Med Sci 2018;73(9):1199–204.

2. Atisha DM, Burr TVR, Allori AC, Puscas L, Erdmann D, Marcus JR. Facial fractures in the aging population. Plast Reconstr Surg 2016;137(2):S87–93.

3. Leal J, Gray AM, Prieto-Alhambra D, Arden NK, Cooper C, Javidb M, et al. Effect of hip fracture on hospital care costs: a population-based study. Osteoporos Int 2016;27(2):549–58.

4. Von Frieden D, Mcguigan F, Wizert A, Rogmark C, Holmberg AH, Woolf AD, et al. Hip fracture, mortality risk, and cause of death over two decades. Osteoporos Int 2016;27(10):2945–53.

5. Tebe C, Martinez-Laguna D, Carbonei-Allelia C, Reyes C, Moreno V, Diez-Perez A, et al. The association between type 2 diabetes mellitus, hip fracture, and post-hip fracture mortality: a multi-state cohort analysis. Osteoporosis Int 2019;30(12):2407–15.

6. Rosenberg EC, Lippman-Bell JJ, Handy M, Soldan SS, Rakhade S, Hilario-Gomez C, et al. Regulation of seizure-induced MeCP2 Ser421 phosphorylation in the developing brain. Neurobiol Dis 2018;115:120–30.

7. Tillittson R, Selfridge J, Koerner MV, Gadalla K, Guy J, Cheng J, et al. Radically truncated MeCP2 rescues Rett syndrome-like neurological defects. Nature 2017;550(7676):398–401.

8. Tao W, Chen C, Wang Y, Zhou W, Jin Y, Mao Y, et al. MeCP2 mediates transgenerational transmission of chronic pain. Prog Neurobiol 2020;189:101790.

9. Barbour KE, Lui LY, Ensrud KE, Hillier TA, LeBlanc ES, Ing SW, et al. The association between type 2 diabetes mellitus, hip fracture, and post-hip fracture mortality: a multi-state cohort analysis. Osteoporosis Int 2019;30(12):2407–15.

10. Cauley JA, Barbour KE, Harrison SI, Sloan VK, Danielson ME, Ensrud KE, et al. Inflammatory markers and risk of hip fracture in older white women: the study of osteoporotic fractures. J Bone Miner Res 2016;29(9):2057–64.

11. Cauley JA, Barbour KE, Harrison SI, Sloan VK, Danielson ME, Ensrud KE, et al. Inflammatory markers and risk of hip and vertebral fractures in men: the osteoporotic fractures in men (MrOS). J Bone Miner Res 2016;31(12):2129–38.

12. I’Connor BD, Zayzafoon M, Farach-Caron MC, Schanen NC. MeCP2 deficiency decreases bone formation and reduces bone volume in a rodent model of Rett syndrome. Bone 2009;45(2):346–56.

13. Dai Z, Wang R, Ang LW, Yuan JM, Koh WP. Bone turnover biomarkers and risk of osteoporotic hip fracture in an Asian population. Bone 2016;83:171–7.

14. Katsanos S, Mavrogenis AF, Kafkas N, Sardu C, Camperidis V, Katsanos P, et al. Cardiac biomarkers predict 1-year mortality in elderly patients undergoing hip fracture surgery. Orthopodics 2017;40(3):e417–24.
14. Mann J, Chu DC, Maxwell A, Oakley F, Zhu NL, Tsukamoto H, et al. MeCP2 controls an epigenetic pathway that promotes myofibroblast transdifferentiation and fibrosis. Gastroenterology 2010;138(2):705–14. 714.e1–4.

15. Chen W, Zhu Q, Shen Y, Zhu H, Wang X, Tao XJ. Inhibition expression of MeCP2 could induce human periodontal ligament fibroblasts apoptosis and reduce osteogenic differentiation capacity. Chin J Clin Phar Ther 2016(11):1228–32.

16. Wang T, Zhang X, Bikle DD. Osteogenic Differentiation of Periosteal Cells During Fracture Healing. J Cell Physiol 2017;232(5):913–21.

17. Cheng G, Chen J, Wang Q, Yang X, Cheng Y, Li Z, et al. Promoting osteogenic differentiation in pre-osteoblasts and reducing tibial fracture healing time using functional nanofibers. Nano Res 2016;11(7):3658–77.

18. Zong C, Cai B, Wen X, Alam S, Chen Y, Guo Y, et al. The role of myofibroblasts in the development of osteoradionecrosis in a newly established rabbit model. J Craniomaxillofac Surg 2016;44(6):725–33.

19. Wang MM, Feng YS, Xing Y, Dong F, Zhang F. Mechanisms involved in the arthrofibrosis formation and treatments following bone fracture. J Back Musculoskeletal Rehabil 2019;32(6):947–54.

20. Ma TT, Li XF, Li WX, Yang Y, Huang C, Meng XM, et al. Geniposide alleviates inflammation by suppressing MeCP2 in mice with carbon tetrachloride-induced acute liver injury and LPS-treated THP-1 cells. Int Immunopharmacol 2015;29(2):739–47.

21. Li C, Jiang S, Liu SQ, Lykken E, Zhao LT, Sevilla J, et al. MeCP2 enforces Foxp3 expression to promote regulatory T cells’ resilience to inflammation. Proc Natl Acad Sci USA 2014;111(27):E2807–16.

22. O’Driscoll CM, Lima MP, Kaufmann WE, Brensler JP. Methyl CpG binding protein 2 deficiency enhances expression of inflammatory cytokines by sustaining NF-κB signaling in myeloid derived cells. J Neuroimmunol 2015;283:23–9.

23. Yoo JI, Ha YC, Choi H, Kim KH, Lee YK, Koo KH, et al. Malnutrition and chronic inflammation as risk factors for sarcopenia in elderly patients with hip fracture. Asia Pac J Clin Nutr 2018;27(3):527–32.

24. Saribal D, Hocaoglu-Emre FS, Erdogan S, Bahatiyar N, Caglar Okur S, Mert M. Inflammatory cytokines IL-6 and TNF-α in patients with hip fracture. Osteoporos Int 2019;30(5):1025–31.

25. Bartko J, Reichardt B, Kocijan R, Klaunhofer K, Zwirina J, Behanova M. Inflammatory bowel disease: a nationwide study of hip fracture and mortality risk after hip fracture. J Crohn’s Colitis 2020;14(9):1256–63.